How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
The company has strengthened its cash position following a successful funding round and is actively engaging with the FDA to support pivotal trial design for multiple chronic cough indications. With its clinical pipeline moving closer to late-stage trials, we'll look at how upcoming regulatory milestones shape Trevi's investment narrative. AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. What Is Trevi Therapeutics' Investment Narrative? To see an opportunity in Trevi Therapeutics right now, you really have to believe in the company's bet that Haduvio will carve out a meaningful role in the chronic cough treatment market. The latest quarterly results affirm Trevi's steady progress and address one of the most immediate investor questions: does the current cash runway and recent trial success shift near-term catalysts o
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial OfficerPR Newswire
- Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.MarketBeat
- Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]Seeking Alpha
- Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 12/5/25 - Form 8-K
- 12/3/25 - Form 4
- 11/14/25 - Form SCHEDULE
- TRVI's page on the SEC website